rolipram has been researched along with Allergic Encephalomyelitis in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "PDE4 inhibition suppresses experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS)." | 1.39 | Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis. ( Ballester, A; Ballester, S; Bravo, B; Eguiluz, C; Gil, C; Gómez-Pérez, R; González-García, C; Martínez, A; Redondo, M, 2013) |
| "Multiple sclerosis is an unmet disease in which pathologies on the immune system, T-cells, and specific neural cells are involved simultaneously." | 1.38 | Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds. ( Alonso-Gil, S; Brea, J; Cadavid, MI; Campillo, NE; Gil, C; Loza, MI; Martin-Alvarez, R; Martinez, A; Mengod, G; Morales-García, JA; Paul-Fernandez, N; Perez, C; Perez, DI; Perez-Castillo, A; Redondo, M; Soteras, I; Val, C, 2012) |
| "Rolipram suppresses experimental autoimmune encephalomyelitis (EAE) and diminishes cell infiltration of the central nervous system (CNS)." | 1.33 | Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis. ( Arriaga, A; Ballester, S; García-Merino, A; González, P; Puerta, C; Sánchez, AJ, 2005) |
| "Using Lewis rats with experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis, we recently found a decrease in cannabinoid CB1 receptors mainly circumscribed to the basal ganglia, which could be related to the motor disturbances characteristic of these rats." | 1.33 | Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. ( Cabranes, A; de Lago, E; Di Marzo, V; Fernández-Ruiz, J; Fezza, F; García-Merino, A; Mestre, L; Ramos, JA; Sánchez, A; Valenti, M; Venderova, K, 2005) |
| "Rolipram-treated and control animals equally developed circulating antibodies to myelin basic protein." | 1.29 | Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. ( Davis, RL; Faulds, D; Genain, CP; Hauser, SL; Hedgpeth, J; Li, Y; Nguyen, MH; Roberts, T; Uccelli, A, 1995) |
| "Rolipram has extensively been studied in humans for the treatment of depression, but has not yet been marketed." | 1.29 | The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. ( Fontana, A; Lichtenfels, R; Löschmann, PA; Meyermann, R; Northoff, GH; Riethmüller, A; Sommer, N; Steinbach, JP; Steinbrecher, A; Weller, M, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Redondo, M | 2 |
| Brea, J | 1 |
| Perez, DI | 1 |
| Soteras, I | 1 |
| Val, C | 1 |
| Perez, C | 1 |
| Morales-García, JA | 1 |
| Alonso-Gil, S | 1 |
| Paul-Fernandez, N | 1 |
| Martin-Alvarez, R | 1 |
| Cadavid, MI | 1 |
| Loza, MI | 1 |
| Perez-Castillo, A | 1 |
| Mengod, G | 1 |
| Campillo, NE | 1 |
| Martinez, A | 2 |
| Gil, C | 2 |
| Sunke, R | 1 |
| Bankala, R | 1 |
| Thirupataiah, B | 1 |
| Ramarao, EVVS | 1 |
| Kumar, JS | 1 |
| Doss, HM | 1 |
| Medishetti, R | 1 |
| Kulkarni, P | 1 |
| Kapavarapu, RK | 1 |
| Rasool, M | 1 |
| Mudgal, J | 1 |
| Mathew, JE | 1 |
| Shenoy, GG | 1 |
| Parsa, KVL | 1 |
| Pal, M | 1 |
| González-García, C | 1 |
| Bravo, B | 1 |
| Ballester, A | 1 |
| Gómez-Pérez, R | 1 |
| Eguiluz, C | 1 |
| Ballester, S | 2 |
| Paintlia, AS | 2 |
| Paintlia, MK | 2 |
| Singh, I | 2 |
| Skoff, RB | 1 |
| Singh, AK | 2 |
| Sánchez, AJ | 1 |
| Puerta, C | 2 |
| González, P | 1 |
| Arriaga, A | 1 |
| García-Merino, A | 3 |
| Cabranes, A | 1 |
| Venderova, K | 1 |
| de Lago, E | 1 |
| Fezza, F | 1 |
| Sánchez, A | 1 |
| Mestre, L | 1 |
| Valenti, M | 1 |
| Ramos, JA | 1 |
| Di Marzo, V | 1 |
| Fernández-Ruiz, J | 1 |
| Moore, CS | 1 |
| Earl, N | 1 |
| Frenette, R | 1 |
| Styhler, A | 1 |
| Mancini, JA | 1 |
| Nicholson, DW | 1 |
| Hebb, AL | 1 |
| Owens, T | 1 |
| Robertson, GS | 1 |
| Genain, CP | 1 |
| Roberts, T | 1 |
| Davis, RL | 1 |
| Nguyen, MH | 1 |
| Uccelli, A | 1 |
| Faulds, D | 1 |
| Li, Y | 1 |
| Hedgpeth, J | 1 |
| Hauser, SL | 1 |
| Raine, CS | 1 |
| Sommer, N | 1 |
| Löschmann, PA | 1 |
| Northoff, GH | 1 |
| Weller, M | 1 |
| Steinbrecher, A | 1 |
| Steinbach, JP | 1 |
| Lichtenfels, R | 1 |
| Meyermann, R | 1 |
| Riethmüller, A | 1 |
| Fontana, A | 1 |
| Jung, S | 1 |
| Zielasek, J | 1 |
| Köllner, G | 1 |
| Donhauser, T | 1 |
| Toyka, K | 1 |
| Hartung, HP | 1 |
| Martínez, I | 1 |
| Redondo, C | 1 |
| Folcik, VA | 1 |
| Smith, T | 1 |
| O'Bryant, S | 1 |
| Kawczak, JA | 1 |
| Zhu, B | 1 |
| Sakurai, H | 1 |
| Kajiwara, A | 1 |
| Staddon, JM | 1 |
| Glabinski, A | 1 |
| Chernosky, AL | 1 |
| Tani, M | 1 |
| Johnson, JM | 1 |
| Tuohy, VK | 1 |
| Rubin, LL | 1 |
| Ransohoff, RM | 1 |
| 't Hart, BA | 1 |
| van Meurs, M | 1 |
| Brok, HP | 1 |
| Massacesi, L | 1 |
| Bauer, J | 1 |
| Boon, L | 1 |
| Bontrop, RE | 1 |
| Laman, JD | 1 |
| Agnello, D | 1 |
| Carvelli, L | 1 |
| Muzio, V | 1 |
| Villa, P | 1 |
| Bottazzi, B | 1 |
| Polentarutti, N | 1 |
| Mennini, T | 1 |
| Mantovani, A | 1 |
| Ghezzi, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety, Tolerability & Effects of Rolipram on Inflammatory Activity in the Central Nervous System in Multiple Sclerosis. A Phase II, Open Label Crossover Trial Using MRI as an Outcome Measure[NCT00011375] | Phase 2 | 52 participants | Interventional | 2001-02-28 | Completed | ||
| Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus in Peripheral Blood of Patients[NCT02489877] | 84 participants (Anticipated) | Observational | 2015-07-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for rolipram and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Multiple sclerosis: TNF revisited, with promise.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Humans; Multiple Sclerosis; Phosphodiesterase | 1995 |
15 other studies available for rolipram and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood-Brain Barrier; Cell Survival; Cyclic AMP; Cy | 2012 |
InCl
Topics: Animals; Arthritis; Cyclic Nucleotide Phosphodiesterases, Type 4; Encephalomyelitis, Autoimmune, Exp | 2019 |
Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis.
Topics: Animals; Anti-Inflammatory Agents; Brain; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Typ | 2013 |
Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis.
Topics: Animals; Central Nervous System; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Disease Models, A | 2009 |
Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis.
Topics: Animals; Demyelinating Diseases; Drug Synergism; Drug Therapy, Combination; Encephalomyelitis, Autoi | 2008 |
Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis.
Topics: Animals; Cell Movement; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; D | 2005 |
Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Arachidonic Acids; Basal Ganglia; Brain; Cannabinoid R | 2005 |
Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Body Weight; Cyclic Nucleotide Phosphodiesterases, Typ | 2006 |
Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Base Sequence; Brain Chemistry; Callithrix; Central Ne | 1995 |
The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis.
Topics: Animals; Antidepressive Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Encephalomyelitis, Auto | 1995 |
Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats.
Topics: Animals; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Female; Immu | 1996 |
Type IV phosphodiesterase inhibition in experimental allergic encephalomyelitis of Lewis rats: sequential gene expression analysis of cytokines, adhesion molecules and the inducible nitric oxide synthase.
Topics: Animals; Cell Adhesion Molecules; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Gene Expre | 1999 |
Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Acute Disease; Animals; Blood-Brain Barrier; Brain Edema; Centr | 1999 |
A new primate model for multiple sclerosis in the common marmoset.
Topics: Acute Disease; Animals; Antibodies, Monoclonal; Autoimmune Diseases; Callithrix; CD40 Antigens; Cebi | 2000 |
Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: relation to inflammatory cytokines and modulation by dexamethasone and rolipram.
Topics: Animals; Antineoplastic Agents; Benzodiazepines; Binding Sites; C-Reactive Protein; Dexamethasone; E | 2000 |